Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients following its approval by the U.S. Food and Drug Administration for the treatment of steroid-refractory acute graft-versus-host disease. Although there is extensive experience using ruxolitinib for patients with myeloproliferative neoplasms, the biologic effects and clinical implications of its dosing, tapering, and discontinuation for allogeneic HCT recipients are incompletely characterized. We describe three allogeneic HCT recipients who developed acute hypoxemic respiratory failure within 3 months of ruxolitinib discontinuation. Radiographic findings included marked bilateral ground-glass opacities. Systemic corticosteroids and reinitiation of ruxolitinib resulted in rapid clinical improvement in all three patients. All three patients achieved a significant clinical response, with decrease in oxygen requirement and improvement in radiographic changes. Given the increasing use of ruxolitinib in allogeneic HCT recipients, there is significant impetus to characterize the biologic and clinical effects resulting from discontinuation of ruxolitinib, to better tailor treatment plans and prevent potential adverse effects.

References Powered by Scopus

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

515Citations
N/AReaders
Get full text

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial

210Citations
N/AReaders
Get full text

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

198Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Anandappa, A. J., Hobbs, G. S., Dey, B. R., El-Jawahri, A., Frigault, M. J., McAfee, S. L., … DeFilipp, Z. (2021). Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients. Oncologist, 26(11), e2082–e2085. https://doi.org/10.1002/onco.13903

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

50%

Sports and Recreations 1

50%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 3

Save time finding and organizing research with Mendeley

Sign up for free